Altimmune, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jerome Benedict Durso
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 910 Clopper Road Gaithersburg MD United States of America 20878
- IPO Date
- May 26, 2017
- CIK
- 0001326190
- Website
- altimmune.com
- Similar Companies
- Business
- Altimmune, Inc. is a biopharmaceutical company in the late clinical stage, dedicated to developing innovative peptide-based therapies for liver and cardiometabolic conditions. The company's main therapeutic candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing evaluation for several indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Regarding pemvidutide's progress, the IMPACT Phase 2b MASH trial has completed enrollment, with 24-week data already published in The Lancet and 48-week data anticipated by the end of 2025. An End-of-Phase 2 meeting with the FDA is scheduled for late 2025, with plans to initiate Phase 3 trials in 2026. Pemvidutide has received Fast Track designation from the U.S. FDA for MASH and AUD. Furthermore, Phase 2 trials for AUD (RECLAIM study) and ALD (RESTORE study) are actively enrolling or have completed enrollment. Previously, Altimmune was developing HepTcell, an immunotherapeutic for chronic hepatitis B. However, the company discontinued its development in March 2024 following Phase 2 trial results that were deemed insufficient to warrant further advancement. The company focuses entirely on advancing pemvidutide through clinical development. Altimmune, Inc. maintains its headquarters in Gaithersburg, Maryland.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune Q2 Earnings Call Highlights
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune's Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup